Tango Therapeutics Ownership
| TNGX Stock | USD 10.33 0.30 2.99% |
Shares in Circulation | First Issued 2020-03-31 | Previous Quarter 110.5 M | Current Value 111 M | Avarage Shares Outstanding 81.9 M | Quarterly Volatility 32.7 M |
Tango Stock Ownership Analysis
About 98.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.91. Tango Therapeutics had not issued any dividends in recent years. Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts. Tango Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 103 people. To find out more about Tango Therapeutics contact Barbara MD at 857 320 4900 or learn more at https://www.tangotx.com.Besides selling stocks to institutional investors, Tango Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Tango Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Tango Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Tango Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Tango Therapeutics Insider Trades History
About 5.0% of Tango Therapeutics are currently held by insiders. Unlike Tango Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Tango Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Tango Therapeutics' insider trades
Tango Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Tango Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Tango Therapeutics backward and forwards among themselves. Tango Therapeutics' institutional investor refers to the entity that pools money to purchase Tango Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Siren, L.l.c. | 2025-06-30 | 3.4 M | Balyasny Asset Management Llc | 2025-06-30 | 3.2 M | T. Rowe Price Investment Management,inc. | 2025-06-30 | 3.2 M | Bain Capital Life Sciences Investors, Llc | 2025-06-30 | 2.7 M | Ra Capital Management, Llc | 2025-06-30 | 2 M | Millennium Management Llc | 2025-06-30 | 1.8 M | Geode Capital Management, Llc | 2025-06-30 | 1.8 M | Marshall Wace Asset Management Ltd | 2025-06-30 | 1.7 M | Commodore Capital Lp | 2025-06-30 | 1.5 M | Trv Gp Iv, Llc | 2025-06-30 | 16.9 M | Tcg Crossover Management, Llc | 2025-06-30 | 10.7 M |
Tango Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tango Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tango Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Tango Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Tango Therapeutics Corporate Filings
| 21st of November 2025 Other Reports | ViewVerify | |
| 14th of November 2025 Other Reports | ViewVerify | |
| 13th of November 2025 Other Reports | ViewVerify | |
10Q | 4th of November 2025 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Tango Stock Analysis
When running Tango Therapeutics' price analysis, check to measure Tango Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tango Therapeutics is operating at the current time. Most of Tango Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tango Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tango Therapeutics' price. Additionally, you may evaluate how the addition of Tango Therapeutics to your portfolios can decrease your overall portfolio volatility.